KR101323411B1 - Ｒａｇｅ 융합 단백질 및 이의 사용 방법 - Google Patents

Ｒａｇｅ 융합 단백질 및 이의 사용 방법 Download PDF

Info

Publication number
KR101323411B1
KR101323411B1 KR1020077005152A KR20077005152A KR101323411B1 KR 101323411 B1 KR101323411 B1 KR 101323411B1 KR 1020077005152 A KR1020077005152 A KR 1020077005152A KR 20077005152 A KR20077005152 A KR 20077005152A KR 101323411 B1 KR101323411 B1 KR 101323411B1
Authority
KR
South Korea
Prior art keywords
rage
pro
gly
val
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077005152A
Other languages
English (en)
Korean (ko)
Other versions
KR20070039981A (ko
Inventor
아드난 엠.엠. 므잘리
예 이. 티안
제프리 씨. 웹스터
로버트 로슬린
Original Assignee
트랜스테크 파르마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트랜스테크 파르마, 인크. filed Critical 트랜스테크 파르마, 인크.
Publication of KR20070039981A publication Critical patent/KR20070039981A/ko
Application granted granted Critical
Publication of KR101323411B1 publication Critical patent/KR101323411B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
KR1020077005152A 2004-08-03 2005-08-03 Ｒａｇｅ 융합 단백질 및 이의 사용 방법 Expired - Fee Related KR101323411B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59855504P 2004-08-03 2004-08-03
US60/598,555 2004-08-03
PCT/US2005/027705 WO2006017647A1 (en) 2004-08-03 2005-08-03 Rage fusion proteins and methods of use

Publications (2)

Publication Number Publication Date
KR20070039981A KR20070039981A (ko) 2007-04-13
KR101323411B1 true KR101323411B1 (ko) 2013-10-30

Family

ID=35149359

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077005152A Expired - Fee Related KR101323411B1 (ko) 2004-08-03 2005-08-03 Ｒａｇｅ 융합 단백질 및 이의 사용 방법

Country Status (23)

Country Link
US (5) US7901688B2 (enExample)
EP (1) EP1781700B1 (enExample)
JP (1) JP5188804B2 (enExample)
KR (1) KR101323411B1 (enExample)
CN (1) CN1993378A (enExample)
AP (1) AP2007003869A0 (enExample)
AU (1) AU2005271452B2 (enExample)
BR (1) BRPI0514052A (enExample)
CA (1) CA2570324C (enExample)
CR (1) CR20110556A (enExample)
EA (1) EA012082B1 (enExample)
EC (1) ECSP077221A (enExample)
ES (1) ES2473587T3 (enExample)
GE (1) GEP20105110B (enExample)
IL (1) IL180554A (enExample)
MA (1) MA29067B1 (enExample)
MX (1) MX2007001559A (enExample)
NO (1) NO20065949L (enExample)
NZ (1) NZ552128A (enExample)
TN (1) TNSN07037A1 (enExample)
UA (1) UA93356C2 (enExample)
WO (1) WO2006017647A1 (enExample)
ZA (2) ZA200700643B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005026209A2 (en) * 2003-09-11 2005-03-24 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
EP1781700B1 (en) 2004-08-03 2014-03-19 TransTech Pharma, LLC Rage fusion proteins and methods of use
US20060078562A1 (en) * 2004-08-03 2006-04-13 Mjalli Adnan M RAGE fusion proteins and methods of use
WO2006119510A2 (en) * 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
WO2007076200A2 (en) * 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
RU2431804C2 (ru) * 2005-12-23 2011-10-20 ДжиКоудер Системз АБ Шаблон позиционирования
AU2007215503A1 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
WO2007130302A2 (en) * 2006-05-05 2007-11-15 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
KR101722305B1 (ko) 2007-01-30 2017-03-31 에피백스, 인크. 조절 ｔ 세포 에피토프, 그의 조성물 및 용도
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
WO2008153957A1 (en) * 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Uses of rage antagonists for treating obesity and related diseases
KR101595634B1 (ko) * 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
JP5620106B2 (ja) * 2007-10-24 2014-11-05 株式会社糖鎖工学研究所 増強されたエフェクター機能を有するポリペプチド
NL2001554C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001555C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001553C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001552C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001557C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001556C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001558C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001551C2 (nl) * 2008-05-06 2009-05-07 Transtech Pharma Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
DK2789684T3 (en) 2008-05-23 2017-02-20 Siwa Corp Methods and compositions for facilitating regeneration
EP2421892A1 (en) 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2011100508A2 (en) * 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
EP3511017A1 (en) 2010-09-27 2019-07-17 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CA2839619C (en) 2011-06-28 2021-11-16 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
IN2013MN02442A (enExample) * 2011-06-28 2015-06-12 Inhibrx Llc
HK1207097A1 (en) * 2012-09-07 2016-01-22 Sanofi Fusion proteins for treating a metabolic syndrome
WO2015023165A1 (ko) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 염증조절복합체 및 ｓｔａｔ３ 신호분자 차단을 통한 면역조절능 최적화된 안정화 중간엽줄기세포
AU2015318036B2 (en) * 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
EP4067386A1 (en) 2016-02-19 2022-10-05 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
US11958900B2 (en) 2016-04-15 2024-04-16 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
US12145993B2 (en) * 2016-06-08 2024-11-19 Shanghai Jiao Tong University School Of Medicine Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
WO2018152375A2 (en) * 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered polypeptides
EP3609923A1 (en) 2017-04-13 2020-02-19 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
US10913784B2 (en) 2018-09-14 2021-02-09 BioAge Labs, Inc. RAGE fusion proteins with improved stability and ligand binding affinity and uses thereof
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016229A2 (en) * 2002-08-16 2004-02-26 Wyeth Compositions and methods for treating rage-associated disorders

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
EP0672141B1 (en) 1992-10-23 2003-05-14 Immunex Corporation Methods of preparing soluble, oligomeric proteins
NO315930B1 (no) * 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
EP1327887A3 (en) * 1995-01-18 2008-12-10 Synvista Therapeutics, Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation end products
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
JPH11504316A (ja) * 1995-04-05 1999-04-20 ザ ピコワー インスティテュート フォア メディカル リサーチ 進行性グリコシル化終末産物に結合する薬剤及びその使用方法
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
AU2696097A (en) 1996-04-16 1997-11-07 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
WO1998040071A1 (en) 1997-03-11 1998-09-17 The General Hospital Corporation Identification of agents for use in the treatment of alzheimer's disease
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6380165B1 (en) * 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6706683B1 (en) 1998-09-29 2004-03-16 Asahi Kasei Pharma Corporation Method for controlling the release of granules
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
HK1041293B (en) * 1998-10-06 2008-01-25 The Trustees Of Columbia University In The City Of New York Extracellular novel rage binding protein (en-rage) and uses thereof
US6197294B1 (en) * 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
US6605642B2 (en) * 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
EP1307219A4 (en) 1999-08-13 2005-04-06 Univ Columbia METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF
WO2001018060A1 (fr) 1999-09-08 2001-03-15 Toray Industries, Inc. Materiaux de circulation extracorporelle, adsorbants de facteurs de complication diabetique, reservoirs servant a eliminer des facteurs de complication diabetique et procede d'elimination de facteurs de complication diabetique
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
EP1287162A2 (en) 1999-10-21 2003-03-05 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
CA2382165A1 (en) * 1999-12-08 2001-06-14 Genset S.A. Full-length human cdnas encoding potentially secreted proteins
DE60129008T2 (de) * 2000-04-14 2007-10-11 Niadyne Corp., Tucson Methode zur identifizierung von regulatoren der bildung von protein-age-derivaten
US6727353B2 (en) * 2000-04-14 2004-04-27 Icagen, Inc. Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain
AU2001255436A1 (en) 2000-04-17 2001-10-30 Transtech Pharma Protein expression system arrays and use in biological screening
US20020037538A1 (en) 2000-05-09 2002-03-28 Trepicchio William L. Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
WO2002013262A2 (en) * 2000-08-07 2002-02-14 Amberwave Systems Corporation Gate technology for strained surface channel and strained buried channel mosfet devices
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
US6563015B1 (en) 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
EA200300442A1 (ru) * 2000-10-02 2003-10-30 Редди Ю Эс Терапьютикс, Инк. Способы и композиции для лечения воспалительных заболеваний
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US20050244849A1 (en) * 2000-12-15 2005-11-03 Genetics Institute, Llc Screening assays for rheumatoid arthritis
PL366250A1 (en) 2000-12-29 2005-01-24 Reddy Us Therapeutics, Inc. Detection of compounds that modulate inflammatory responses
US6946277B2 (en) 2001-01-31 2005-09-20 Council Of Scientific And Industrial Research Method for enhancing cellobiase activity of termitomyces clypeatus using a glycosylation inhibitor
KR20040074587A (ko) * 2001-02-19 2004-08-25 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 인공 단백질
DE10109466B4 (de) 2001-02-28 2008-01-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Mittel zur Modifikation humaner Angiogenese
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
ES2242864T3 (es) * 2001-03-22 2005-11-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Procedimientos y aparatos para el analisis cualitativo y cuantitativo sin gel de proteoma, y sus usos.
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20060241284A1 (en) 2002-12-13 2006-10-26 Juha Kuja-Panula Transmembrane protein amigo and uses thereof
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2004100890A2 (en) * 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Rage g82s-related methods and compositions for treating inflammatory disorders
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
ZA200601810B (en) * 2003-09-05 2008-05-28 Univ Columbia Rage-related methods and compositions for treating glomerular injury
WO2005042032A1 (en) * 2003-10-31 2005-05-12 The Trustees Of Columbia University In The City Of New York Methods for treating multiple sclerosis
US8003613B2 (en) 2003-11-17 2011-08-23 University Of Florida Research Foundation, Inc. Methods and compositions for inducing apoptosis
WO2005051995A2 (en) 2003-11-19 2005-06-09 Curagen Corporation Novel advanced glycosylation end product-specific receptor-like protein and nucleic acids encoding same
GB0330079D0 (en) 2003-12-20 2004-02-04 Bioinvent Int Ab Vaccine
CN100342017C (zh) 2004-05-10 2007-10-10 中国医学科学院肿瘤医院肿瘤研究所 基因重组趋化抗原疫苗
US20080305073A1 (en) 2004-07-02 2008-12-11 Barone Domenico G Therapeutic Agents for the Treatment of Hmgb1-Related Pathologies
US20060012414A1 (en) * 2004-07-15 2006-01-19 Texas Instruments Incorporated Circuit and method for generating a polyphase clock signal and system incorporating the same
EP1771565B1 (en) 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
EP1814576A2 (en) 2004-07-20 2007-08-08 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US20060078562A1 (en) * 2004-08-03 2006-04-13 Mjalli Adnan M RAGE fusion proteins and methods of use
EP1781700B1 (en) 2004-08-03 2014-03-19 TransTech Pharma, LLC Rage fusion proteins and methods of use
CA2581505A1 (en) 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
WO2006119510A2 (en) 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
AU2007215503A1 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
WO2007130302A2 (en) 2006-05-05 2007-11-15 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
WO2008100470A2 (en) 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
KR101595634B1 (ko) 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016229A2 (en) * 2002-08-16 2004-02-26 Wyeth Compositions and methods for treating rage-associated disorders

Also Published As

Publication number Publication date
GEP20105110B (en) 2010-11-10
ZA200906459B (en) 2010-05-26
US8877192B2 (en) 2014-11-04
UA93356C2 (ru) 2011-02-10
US7981423B2 (en) 2011-07-19
AU2005271452A1 (en) 2006-02-16
AU2005271452B2 (en) 2011-11-03
NZ552128A (en) 2009-09-25
CA2570324A1 (en) 2006-02-16
CN1993378A (zh) 2007-07-04
AP2007003869A0 (en) 2007-02-28
JP5188804B2 (ja) 2013-04-24
MX2007001559A (es) 2007-04-10
IL180554A (en) 2013-09-30
ECSP077221A (es) 2007-03-29
US20120171202A1 (en) 2012-07-05
EA200700404A1 (ru) 2007-06-29
IL180554A0 (en) 2007-06-03
US20110124102A1 (en) 2011-05-26
TNSN07037A1 (fr) 2008-06-02
ES2473587T3 (es) 2014-07-07
US20080075733A1 (en) 2008-03-27
US20110244516A1 (en) 2011-10-06
WO2006017647A1 (en) 2006-02-16
US20060030527A1 (en) 2006-02-09
JP2008512988A (ja) 2008-05-01
ZA200700643B (en) 2010-07-28
EA012082B1 (ru) 2009-08-28
CR20110556A (es) 2011-11-10
NO20065949L (no) 2007-01-16
EP1781700B1 (en) 2014-03-19
KR20070039981A (ko) 2007-04-13
EP1781700A1 (en) 2007-05-09
US7901688B2 (en) 2011-03-08
BRPI0514052A (pt) 2008-05-27
CA2570324C (en) 2014-07-22
MA29067B1 (fr) 2007-12-03

Similar Documents

Publication Publication Date Title
KR101323411B1 (ko) Ｒａｇｅ 융합 단백질 및 이의 사용 방법
KR20070057818A (ko) Ｒａｇｅ 융합 단백질 및 이의 사용 방법
NL2000476C2 (nl) Rage-fusie-eiwitten en werkwijzen voor het gebruik ervan.
KR20090008459A (ko) Ｒａｇｅ 융합 단백질, 제제 및 이의 사용 방법
EA027853B1 (ru) Синтетические миметики апелина для лечения сердечной недостаточности
TW201141507A (en) RAGE fusion protein compositions and methods of use
HK1104933A (en) Rage fusion proteins and methods of use
HK1129393A (en) Rage fusion proteins and methods of use
HK1104046A (en) Rage fusion proteins and methods of use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20160921

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20171024

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20171024